Hepatitis B Virus – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV infection for each country, as well as annualized case counts projected to the national population.

The patient populations are forecast over a period of 10 years for all countries.

Clarivate Epidemiology’s HBV infection forecast will answer the following questions:

• How will changes in HBV vaccine coverage impact the prevalence of HBV infections?
• Of all people infected with HBV, how many in each country have been formally diagnosed?
• Of those diagnosed with HBV infection, what percentage in each of the major pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HBV infection over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following hepatitis B populations in the mature markets:

• Total hepatitis B prevalent cases.
• Diagnosed hepatitis B prevalent cases.
• Diagnosed hepatitis B prevalent cases by HBeAg status.
• Diagnosed hepatitis B prevalent cases by liver status.
• Diagnosed hepatitis B prevalent cases by treatment status.

Note: Coverage may vary by country.